



Press Release

European Patent Office grants two key patents for CILIAN's Ciliate expression technology

Münster, Germany, August 2011:

CILIAN AG announces today that it was granted two key patents by the European patent Office. This enables CILIAN AG to expand the IP position for its platform technology, the heterologous expression system CIPEX (Ciliates Performance Expression System). The two patents EP 1848814 and EP 1357190 claim methods for the identification of Protease-restricted Ciliates and selection methods for transformed Ciliates.

CILIAN AG already owns a series of granted patents and has several other applications currently pending claiming platform technology as well as a proprietary drug.

"The granted patents are significant for the development of production strains generated from our Ciliate expression platform" said Dr. Marcus Hartmann, CSO of CILIAN. "These patents protect important elements of the expression technology and safeguard our developmental work in the area of a Ciliate based production system for biopharmaceuticals." Christian Scheiner, CEO of CILIAN AG, concluded.

About Cilian AG

Founded in 2001 by Dr. Marcus Hartmann, CILIAN AG is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of therapeutic proteins. Ciliates are also the source for a new enzyme preparation, which will be developed by the company for enzyme replacement therapy directed at exocrine pancreatic insufficiency.

For further information, visit www.cilian.com or contact:

Cilian AG:

Marcus Hartmann, Ph.D. (CSO)

tel. +49 251 6 20 310

hartmann@cilian.de